Get started

Stockstobuy

SRPT Sarepta Therapeutics Potential Buyout SoonIf you haven`t bought SRPT here: Then you need to know that there is a Massive catalyst coming! Sarepta Therapeutics is going to announce Duchenne muscular dystrophy Phase 3 data for its SRP-9001-301 - (EMBARK) by mid November. This week institutions bought calls worth more than $10Mil that SRPT Sarepta Therapeutics will trade above $135 by November 17. Some even bought the $210 strike price! They also have a big partnership with the giant Roche Holding AG (RHHBY). I think SRPT Sarepta Therapeutics is well positioned for a potential takeover soon! Looking forward to read your opinion about it.
NASDAQ:SRPTLong
by TopgOptions
ACRS Aclaris Therapeutics Potential BuyoutACRS Aclaris Therapeutics has 3 clinical trials releasing topline data this year and sufficient cash to fund their operations through the end of 2025. ACRS is in Piper Sandler`s potential 12 biotech takeovers in 2023. ACRS reached 52 week low today: $5.05. Analysts Price Targets: $21 The Goldman Sachs Group $29 BTIG Research $38 Cantor Fitzgerald $43 HC Wainwright Considering the above, I think ACRS might be an easy +3X! Looking forward to read your opinion about it.
NASDAQ:ACRSLong
by TopgOptions
3
Naga Dhunseri Mid Term Idea with an RR of 1:5, 50% + ROI1) The stock is poised for a multiyear breakout, it has formed an ascending triangle pattern in monthly timeframe indicating a strong up move once after the ATH is broken. 2) Candlesticks show extremely bullish price action. Inside bars in Monthly as well. 3) RSI in monthly and weekly are supportive, moving up after a small correction. For a swing trade - One can enter at the demand 1 level if there is a reversal in hourly / 75 min time frame and look for Target 1 and Target 2 zones as targets. 10% up move. For a mid term trade - One can look to enter at the same demand zone as swing, or once after the ATH is sold off at first and then at a further upside reversal, precisely after a dip and bounce back in Daily timeframe RSI as currently it is inching 90+. As per risk management. For the Mid term, SL can be at 1500. Targets at 3100. Wish you all profits and happy trading!
NSE:NDGLLong
by Rugminik
1
NVAX Novavax Vaccine approved! Buy Opportunity!If you haven`t bought NVAX during the pandemic: Then you need to know that NVAX Novavax's recent achievements in gaining full marketing authorization for its COVID-19 vaccine, Nuvaxovid, in the UK and Singapore, alongside its availability in major U.S. pharmacies, have ignited optimism among investors. These milestones signify a bright future for NVAT stock. The international authorization of Nuvaxovid opens doors to vast markets, enhancing revenue potential and global recognition for Novavax. the EU delayed the approval, but will update its decision by the end of this month. Nuvaxovid's availability at CVS and Rite Aid in the U.S. immediately after regulatory clearance demonstrates its acceptance and accessibility. Nuvaxovid is a protein-based COVID-19 vaccine, different from the mRNA vaccines of PFE and MRNA. My price target is $10 by the end of this month. Looking forward to read your opinion about it.
NASDAQ:NVAXLong
by TopgOptions
LYFT in a bearish channel.LYFT Inc - 30d expiry - We look to Sell at 11.99 (stop at 12.91) Trading within a Bearish Channel formation. The sequence for trading is lower lows and highs. The primary trend remains bearish. Preferred trade is to sell into rallies. The trend of lower highs is located at 12.00. Our profit targets will be 9.81 and 9.41 Resistance: 11.53 / 12.00 / 12.45 Support: 10.75 / 10.30 / 9.72 Please be advised that the in formation presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Everest Fortune Group’). Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Everest Fortune Group
NASDAQ:LYFTShort
by VantageMarkets
EIHOTEL - INVEST & HOLD FOR 2 MONTHSEntry Level : 222 SL : 202 Targets : 242,256,273+ 52wk High : 274.95 52wk Low : 150.35 Mkt Cap : 139.49 B Disclaimer - All information on this page is for educational purposes only, we are not SEBI Registered, Please consult a SEBI registered financial advisor for your financial matters before investing And taking any decision. We are not responsible for any profit/loss you made. Request your support and engagement by liking and commenting & follow to provide encouragement HAPPY TRADING 👍
NSE:EIHOTELLong
by Jagadheesh_JP
SciPlay | SCPLIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. Unfortunately, these high risk investments often have little probability of ever paying off, and many investors pay a price to learn their lesson. While a well funded company may sustain losses for years, it will need to generate a profit eventually, or else investors will move on and the company will wither away. If this kind of company isn't your style, you like companies that generate revenue, and even earn profits, then you may well be interested in SciPlay. While this doesn't necessarily speak to whether it's undervalued, the profitability of the business is enough to warrant some appreciation especially if its growing. If a company can keep growing earnings per share long enough, its share price should eventually follow. That makes EPS growth an attractive quality for any company. We can see that in the last three years SciPlay grew its EPS by 13% per year. That's a good rate of growth, if it can be sustained. Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth. While SciPlay did well to grow revenue over the last year, EBIT margins were dampened at the same time. If EBIT margins are able to stay balanced and this revenue growth continues, then we should see brighter days ahead. You can take a look at the company's revenue and earnings growth trend, in the chart below. Click on the chart to see the exact numbers.You don't drive with your eyes on the rear-view mirror, so you might be more interested in this free report showing analyst forecasts for SciPlay's future profits. It's a good habit to check into a company's remuneration policies to ensure that the CEO and management team aren't putting their own interests before that of the shareholder with excessive salary packages. Our analysis has discovered that the median total compensation for the CEOs of companies like SciPlay with market caps between US$2.0b and US$6.4b is about US$6.7m. The CEO of SciPlay only received US$3.3m in total compensation for the year ending December 2022. That's clearly well below average, so at a glance that arrangement seems generous to shareholders and points to a modest remuneration culture. CEO remuneration levels are not the most important metric for investors, but when the pay is modest, that does support enhanced alignment between the CEO and the ordinary shareholders. It can also be a sign of good governance, more generally. One important encouraging feature of SciPlay is that it is growing profits. To add to this, the modest CEO compensation should tell investors that the directors have an active interest in delivering the best for shareholders. So based on its merits, the stock deserves further research, if not an addition to your watchlist. While we've looked at the quality of the earnings, we haven't yet done any work to value the stock. So if you like to buy cheap, you may want to check if SciPlay is trading on a high P/E or a low P/E, relative to its industry. Shares of SciPlay Corp. rose after the company agreed to be acquired by Light & Wonder. There's always the possibility of doing well buying stocks that are not growing earnings and do not have insiders buying shares. But for those who consider these important metrics, we encourage you to check out companies that do have those features or you can count on our experts.
SLong
by moonypto
CANO Cano Health Potential Buyout!CANO Cano Health was trading at all time low last friday, $0.22! Last year, I remember that following numerous reports suggesting a potential bid, Citigroup analysts have stated that if Humana or CVS Health were to acquire the primary-care provider Cano Health, they might value it at $14 per share. With $2.74 Billions in revenue in 2022, I think Cano Health is too big to go bankrupt. This might be an interesting buy opportunity, in my opinion!
CLong
by TopgOptions
1